Topline results to be presented by Federico Cappuzzo, MD, PhD, on October 25, 2026, at the Annual Meeting of the European Society for Medical Oncology (E...
Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress Data supplements unprecedente...
Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete sy...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, announced positive results from a prospective, multicenter randomized controlled tr...
AAVantgarde Bio (AAVantgarde), the clinical-stage biotechnology company developing genetic medicines for inherited retinal diseases (IRDs) using its propri...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, announced three-year follow-up results from the ovarian cancer cohort of its 400+ patie...
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injecti...
Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at th...
HUTCHMED (China) Limited announces that positive high-level results from the SAFFRON Phase III trial showed ORPATHYS® (savolitinib) plus TAGRISSO®...
Phase 3 VISIONARY study met its key secondary endpoint, showing an annualized estimated eGFR slope of +0.3 (95% CI, -0.4 to 0.9) mL/min/1.73 m²/...
SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a ...
Dasher Neuroscience Holdings Inc. (TPEx: 7829) ("Dasher Neuroscience"), an AI-driven biopharmaceutical company focused on central nervous system (CNS) dr...
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and pote...
© 2026 Biopharma Boardroom. All Rights Reserved.
